Workflow
Nvidia-Intel deal a game-changer for AI and US tech leadership, analysts say
Proactiveinvestors NA· 2025-09-19 00:24
About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...
New Catalysts Build Positive Pressure on Intel Stock
MarketBeat· 2025-09-19 00:22
Intel TodayINTCIntel$32.00 +7.10 (+28.50%) 52-Week Range$17.67▼$32.38Price Target$22.20Add to WatchlistAfter the start of a rally in August that captured significant investor attention, shares of Intel Corporation NASDAQ: INTC have entered a period of consolidation, establishing a new and higher base in the $25 to $26 range. This sideways trading, however, follows a period of positive fundamental development. While the stock chart has been relatively quiet, the company has executed on a series of distinct ...
Is Coherent's R&D Excellence Crucial to Its Competitive Advantage?
ZACKS· 2025-09-19 00:21
Key Takeaways Coherent posted 16.4% top-line growth on AI-related Datacom transceiver demand.COHR's non-GAAP gross margin rose 290 bps to 38.1% in the June quarter.COHR's EBITDA margin of 24% beats industry and rivals despite lower research and development spend.Coherent Corp. (COHR) recorded 16.4% year-over-year growth in its top line during the June quarter, fueled by its AI-related Datacom transceiver business. Backed by research and development (R&D) prowess, COHR’s 800G transceiver, an important factor ...
LLY's Orforglipron Tops NVO's Oral Pill in Diabetes Study: What's Next?
ZACKS· 2025-09-19 00:21
Key Takeaways LLY's orforglipron outperformed Rybelsus in reducing A1C and body weight at 52 weeks.In ACHIEVE-3, orforglipron cut A1C by up to 2.2% at 52 weeks vs. 1.4% with Rybelsus.Orforglipron also improved cholesterol, blood pressure and triglycerides with good tolerability.Eli Lilly (LLY) announced positive top-line data from a late-stage head-to-head study evaluating its once-daily small molecule (non-peptide) oral GLP-1 receptor agonist, orforglipron, compared to Novo Nordisk’s (NVO) Rybelsus (oral s ...
German economy ministry open to idea of SEFE, Uniper tie-up, sources say
Reuters· 2025-09-19 00:20
Germany's economy ministry, which oversees ownership of former Gazprom unit SEFE, is open to the idea of combining all or parts of the business with bailed out peer Uniper , according to two people fa... ...
US Vs. China: Huawei Roadmap to Challenge Nvidia; Nvidia Invests In Intel; Market Discounts Five Cuts - NVIDIA (NASDAQ:NVDA), Intel (NASDAQ:INTC)
Benzinga· 2025-09-19 00:18
To gain an edge, this is what you need to know today.U.S. Vs. ChinaPlease click here for an enlarged chart of Intel Corp INTC.Note the following:This article is about the big picture, not an individual stock.  The chart of INTC stock is being used to illustrate the point.The chart shows INTC stock has jumped about 30% on the news that NVIDIA Corp NVDA will invest $5B in Intel and co-develop chips.The chart shows that INTC stock has broken out.The chart shows INTC stock is nearing zone 2 (resistance).RSI on ...
September BoE: A Pause Amidst "Prominent" Upside Inflation Risks
Seeking Alpha· 2025-09-19 00:18
The Bank of England held rates steady in September, extending its pattern of alternating between cuts and pauses while signaling a more unified stance than in recent months. The decision reflects a balance between acknowledging the progress made in bringing inflation lowerAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own op ...
Qualys: Visible Growth Catalysts To Drive Growth Acceleration
Seeking Alpha· 2025-09-19 00:18
I recommend a buy rating for Qualys, Inc. (NASDAQ: QLYS ). I believe the stock is trading at a discount due to concerns around slowing growth, but given the latest developments in product adoption, partner execution, and theI take a fundamentals-based approach to value investing.I disagree with the common misconception held by many investors that low multiple stocks must be cheap. I look for companies that offer the best long-term durability at the most affordable prices. Consequently, I have a propensity t ...